Haley Oyler’s Post

🔬Expanding ELPIS Study: CDKL5 Ethical Approval Granted in Brazil ✨ We are delighted to share that the Brazilian study has received ethical approval, becoming the first non-European site for the ELPIS study. This milestone builds on the recent approval of the ELPIS study in Ireland, marking another significant step forward in our 🌍 global mission. The #ELPIS study continues to expand its global reach, advancing research on #CDKL5 Deficiency Disorder (CDD) and translating findings into meaningful outcomes for patients and their families. 👪 Patient communities are at the core of #NeuropsychiatricResearch, offering far more than data. Their lived experiences provide invaluable insights into the challenges of this genetic disorder, inspiring hope and guiding families through complex emotional journeys. 👉 Explore our services advancing progress in CDKL5 research: https://ulysses-neuro.ie #Neuroscience #Clinicaltrials #NeuropsychiatricResearch #RareDiseases #TranslationalResearch #ScientificResearch #NeurodevelopmentalDisorders #PatientAdvocacy

TONIGHT! Friday July 12th, 8pm, Yasmin Hurd, PhD JOINS the Marine Biological Laboratory (MBL) Friday Evening Lecture Series presenting “Deciphering Neurobiological Processes of Opioid Addiction towards Novel Interventions”. Online or In-Person | Register Here https://lnkd.in/e2NpkEjG Decoding the neurobiological underpinnings of #PsychiatricDisorders such as #Addiction is critically linked to expanding insights obtained from the human brain which can inform targeted treatments. The important need for the development of novel non-addictive medications is particularly critical today to address the persistent opioid and overdose epidemic crisis facing society worldwide. Here, Dr. Hurd will provide molecular insights gained from post-mortem studies of human heroin users and complementary mechanistic animal studies that identify specific #Epigenetic, #Neurodegenerative, and synaptic plasticity biological processes that offer druggable targets for opioid use disorder. Learn More about Dr. Yamin Hurd's work https://lnkd.in/evQ-w6mB #FriedmanBrainInstitute #NashNeuroscience Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital Graduate School of Biomedical Sciences at the Icahn School of Medicine The Grass Foundation University of Chicago

A heartfelt thank you to Mariana Lenharo and Nature for the kind mention of Kariya Pharmaceuticals and citing for our CSO Christian Hölscher in this enlightening editorial which explores the mechanisms behind the broad clinical potential of GLP-1 analogues and sheds light on the importance of brain penetrance when treating a wide array of CNS conditions from addiction to Parkinson’s and Alzheimer’s Disease.  Enhanced brain-penetrance and target engagement is one of our key scientific premises at Kariya and the reason we believe our drugs show such convincing efficacy in animal models of neurodegeneration, and will one day translate to effective therapies for patients in need! https://lnkd.in/djPZi2C2 #GLP1 #drugdevelopment #BBB #brainpenetration #alzheimersdisease #alzheimersresearch #parkinsonsresearch #parkinsonsdisease #movementdisorders #substanceabusedisorders #addiction #hope #neuroscience #CNS

🚨 Exciting News! 🚨 We're thrilled to announce that Agyany is conducting an Open-Label Phase II Study to assess the safety and efficacy of High-Dose Ambroxol in individuals with newly diagnosed GBA1-related motor and pre-motor Parkinson’s Disease (PD). This multi-center study will include up to 50 participants and aims to evaluate the impact of Ambroxol over a 12-month period plus a further 12-month extesion. We’re exploring the potential to slow disease progression based on various efficacy endpoints. Our goal is to make significant strides in the understanding and treatment of GBA1-related Parkinson's. Stay tuned for updates as we work towards breakthroughs in Parkinson’s disease research! #ParkinsonsResearch #ClinicalTrials #GBA1 #Neuroscience #Agyany #Ambroxol #HealthcareInnovation #Medicine

Tesofensine is a fascinating compound that has garnered attention for its potential impact on weight management. Originally developed for the treatment of neurodegenerative diseases, it was found to have a significant effect on appetite suppression and weight loss during clinical trials. The mechanism of action involves the inhibition of neurotransmitter reuptake, which enhances the levels of dopamine, serotonin, and norepinephrine in the brain. This results in reduced appetite and increased energy expenditure, making it a promising candidate for obesity treatment. As research continues, it's crucial to stay informed about the latest developments and understand both the benefits and potential risks associated with its use. The scientific community is actively exploring its long-term effects and efficacy in different populations. #Tesofensine #WeightManagement #ObesityResearch #Neuroscience #HealthInnovation

#HOT about the human #brain 🧠 in the #NEWS 🗞 #donanemab - new Alzheimer’s drug “At a 10 June meeting at the FDA’s headquarters in Silver Spring, Maryland, all 11 members of an FDA independent scientific advisory committee voted that donanemab, made by Eli Lilly, based in Indianapolis, Indiana, is effective at treating Alzheimer’s, at least in people at early stages of the disease, and that its benefits outweigh its risks”. 🛠 How it works? Donanemab is an antibody that attacks amyloid, a sticky protein that accumulates in the brains of people with Alzheimer’s. ⛑ Issues involved: more than 90% of Lilly’s trial participants were white — and people with Down’s syndrome or genetic mutations that make them more prone to ARIA The FDA’s final decision is expected later this year. https://lnkd.in/gFBcPSQd __ #mentalhealth #brain #health #wellness #humanity #neuroscience #medicine #longivity #HBE #humanbrainexpo #3hbrain #science #AI #brainhealth #ethics #helpfulbrain #innovation #innovationmanagement #events #news #biotech #psychiatry #news #management

Why come to OM1, Inc. for Multiple Sclerosis Real-World Data? With no cure for MS, early diagnosis and effective treatment are the best ways to help reduce damaging effects and improve patients’ quality of life. With the OM1 PremiOM Multiple Sclerosis Dataset, companies can access; 📍 Largest, most representative MS dataset 📍 Longitudinal Outcomes 📍 Patient & MS subtypes 📍 Symptoms, comorbidities, and more 📍 MRI findings available for custom cohorts With OM1’s potential use cases in feasibility, passive safety, comparative effectiveness, natural history, and more OM1 can map the MS patient journey from bench to bedside. Interested in learning more about our Multiple Sclerosis PremiOM dataset and see how OM1 can assist in your current research studies? Check out the following links; 📍 Book a meeting with us: https://lnkd.in/eJcKBAJK 📍 MS eBook: https://lnkd.in/e2GR4xB8 📍 MS Smart Link: https://lnkd.in/efr9VREX #multiplesclerosis #neuroscience #patientjourneys #rwe

“Yale is an incredible place to cross scientific boundaries.”—John Krystal, MD, in conversation with Freedom Biosciences co-founder and CEO Dina Burkitbayeva. The event was part of the Innovation and Entrepreneurship Seminar series co-hosted with Yale Pathology. Dr. Krystal discussed his pioneering research with Dr. Robert Berman that first demonstrated ketamine’s rapid antidepressant effects and directly led to the FDA-approved Esketamine spray. The co-founders also discussed translational neuroscience and the path for bringing novel therapeutics to market, the importance of exploring drug interactions in psychiatry, and the current funding environment for biotech and life sciences ventures. Freedom Biosciences, a Yale University spinout co-founded by Dr. Krystal is creating the next generation of ketamine-based and neuropsychiatric pharmaceuticals to develop more viable and efficacious treatment alternatives for millions of people currently suffering from debilitating mental health disorders. #Yale #YaleVentures #MentalHealth #Neuroscience #Biotech

The Rockefeller University disclosed biological markers which are molecular markers and predictive of brain pathology and clinical status and/or outcome in Parkinson’s disease (PD). The invention provides genes, RNA and protein markers that are associated with, relevant to, or predictive of Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD), Parkinson’s disease with dyskinesia or Parkinson’s disease duration. The present invention further provides methods, kits and markers for the identification and monitoring of disease and disease aspects in Parkinson’s patients and their application as markers and targets in and for evaluating, monitoring and treatment of Parkinson’s disease and relevant pathologies and conditions associated with or developing in Parkinson’s disease. https://buff.ly/3CN8C9r #mentalhealth #brain #health #wellness #humanity #psychology #healthybrain #happybrain #neuroscience #HBE #humanbrainexpo #3hbrain #science #AI #brainhealth #ethics #helpfulbrain #innovation #innovationmanagement #events #news #biotech #psychiatry

📘 Exciting new release: "A Review of Diverse Neurological Disorders: Pathophysiology, Molecular Mechanisms, and Therapeutics"! Edited by Rameshwar Nath Chaurasia, Sunny Ohia, Debasis Bagchi. This comprehensive book offers an unparalleled compilation of the current understanding of neurodegenerative disorders. It explores the origins of mental disorders, including bacterial and fungal invasions, viral assaults, and genetic predispositions, providing readers with a thorough grasp of the neurological landscape. Key topics include: - Neuroinflammation and axonal pathology - The intricate relationship between diet, gut microbiomes, and cognitive decline - The role of probiotics and natural bioactive compounds in preventing conditions like Parkinson’s, Alzheimer’s, and ALS - In-depth analyses of vitamins, micronutrients, antioxidants, and nutraceuticals for neuroprotection Each chapter dissects the intricacies of conditions from central nervous system tuberculosis to the involvement of endocannabinoids in rabies infection. This book not only reviews the current understanding but also lays the groundwork for future treatments and innovations. A must-read for neurophysiologists, neurobiologists, neurologists, and anyone interested in the future of neurological disorder treatments. Get your copy today: https://bit.ly/4ehbnOr #Neuroscience #Neurodegeneration #NewRelease #Neuroinflammation #BrainHealth #MentalHealth #Neuroprotection #Research #HealthcareInnovation